Latest news

• Novartis raises 2019 guidance as new products gather speed

  from new prostate cancer therapy Lutathera, Kisqali (ribociclib) for breast cancer and CAR-T Kymriah (tisagenlecleucel).

• Kisqali combination follows Verzenio onto Cancer Drugs Fund

  Drug must prove its value via managed access route. Novartis’ Kisqali has been recommended for use on the Cancer Drugs Fund (CDF) for second line use in combination with fulvestrant in ... Ibrance and Kisqali gained NICE approval for first line

• Solid Q1 results lift Pfizer as it waits for pipeline boost

  The CDK 4/6 inhibitor looks set to remain one of Pfizer’s biggest growth brands – despite competition from rival products such as Lilly’s Verzenio (abemaciclib) and Kisqali (ribociclib) from

• Alcon spun off, leaner Novartis raises profit forecast

  treatments Lutathera ($106m), Promacta ($307m), Kisqali ($91m) and Kymriah ($45m).

• NICE says no to Novartis’ Kisqali combo in breast cancer

  Double blow after Lilly rival recommended. Novartis’ hopes of a boost for under-performing breast cancer drug Kisqali have been hit by a negative verdict from NICE. ... Early signs are that Lilly’s drug is starting to accelerate even as Kisqali slows